Literature DB >> 11396806

Markers of cystic fibrosis-associated liver disease.

M R Narkewicz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11396806     DOI： 10.1097/00005176-200104000-00005

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  3 in total

1.  Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials.

Authors:  Nicole Mayer-Hamblett; Margaret Kloster; Bonnie W Ramsey; Michael R Narkewicz; Lisa Saiman; Christopher H Goss
Journal:  Contemp Clin Trials       Date:  2012-11-29       Impact factor: 2.226

2.  Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis.

Authors:  Sławomira Drzymała-Czyż; Patrycja Krzyżanowska-Jankowska; Krzysztof Dziedzic; Aleksandra Lisowska; Szymon Kurek; Joanna Goździk-Spychalska; Victoria Kononets; Dagmara Woźniak; Edyta Mądry; Jarosław Walkowiak
Journal:  Biomolecules       Date:  2021-02-19

3.  Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease?

Authors:  C Lemaitre; S Dominique; E Billoud; M Eliezer; H Montialoux; M Quillard; G Riachi; E Koning; H Morisse-Pradier; G Savoye; C Savoye-Collet; O Goria
Journal:  Can Respir J       Date:  2016-06-26       Impact factor: 2.409
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.